

Oklahoma Health Care Authority

Drug Utilization Review Board

(DUR Board)

Meeting – December 11, 2024 @ 4:00pm

at the

Oklahoma Health Care Authority (OHCA)

4345 N. Lincoln Blvd.

Oklahoma City, Oklahoma 73105

NOTE: *The DUR Board will meet at 4:00pm at OHCA (see address above). There will be Zoom access to this meeting; however, Zoom access will be set up in view-only mode with no voting, speaking, video, or chat box privileges. Zoom access will allow for viewing of the presentation slides as well as audio of the presentations and discussion during the meeting; however, the DUR Board meeting will not be delayed or rescheduled due to any technical issues that may arise.*

AGENDA

Discussion and action on the following items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call to Order

A. Roll Call – Dr. Wilcox

DUR Board Members:

Mr. Kenneth Foster –	participating in person
Dr. Megan Hanner –	participating in person
Dr. Bret Haymore –	participating in person
Dr. John Muchmore –	participating in person
Dr. Lee Muñoz –	participating in person
Dr. James Osborne –	participating in person
Dr. Edna Patatanian –	participating in person
Dr. Vineetha Thomas –	participating in person
Dr. Beth Walton –	participating in person

Viewing Access Only via Zoom:

Please register for the meeting at:

https://oklahoma.zoom.us/webinar/register/WN_94lCoSe9Ty2msgsLMqg2Ww

After registering, you will receive a confirmation email containing information about joining the webinar.

Or join by phone:

Dial: +1-602-753-0140 or +1-669-219-2599

Webinar ID: 958 2294 2095

Passcode: 65079339

Public Comment for Meeting:

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting the DUR Board page on the OHCA website at www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board and completing the [Speaker Registration Form](#). Completed Speaker Registration forms should be submitted to DURPublicComment@okhca.org. Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.
- Any speakers who sign up for public comment must attend the DUR Board meeting in person at OHCA (see above address). Public comment through Zoom will not be allowed for the DUR Board meeting.

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum

- A. Acknowledgement of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

- A. November 13, 2024 DUR Board Meeting Minutes
- B. November 13, 2024 DUR Board Recommendations Memorandum
- C. Correspondence

Items to be presented by Dr. Metts, Dr. Snyder, Dr. Muchmore, Chairman:

4. Update on Medication Coverage Authorization Unit/SoonerCare Opioid Initiative Update – See Appendix B

- A. Pharmacy Help Desk Activity for October 2024
- B. Medication Coverage Activity for October 2024
- C. SoonerCare Opioid Initiative Update

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

5. SoonerCare Maintenance Drug List – See Appendix C

- A. Introduction
- B. Maintenance Drug List
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

6. Action Item – Vote to Prior Authorize Ebglyss™ (Lebrikizumab) and Update the Approval Criteria for the Atopic Dermatitis Medications – See Appendix D

- A. Market News and Updates
- B. Ebglyss™ (Lebrikizumab) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

7. Action Item – Vote to Prior Authorize Ohtuvayre™ (Ensifentrine) and Update the Approval Criteria for the Asthma and Chronic Obstructive Pulmonary Disease (COPD) Maintenance Medications – See Appendix E

- A. Market News and Updates
- B. Ohtuvayre™ (Ensifentrine) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

8. Action Item – Vote to Prior Authorize Nemluvio® (Nemolizumab-ilto) – See Appendix F

- A. Market News and Updates
- B. Nemluvio® (Nemolizumab-ilto) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Sinko, Dr. Muchmore, Chairman:

9. Action Item – Annual Review of Skin Cancer Medications – See Appendix G

- A. Current Prior Authorization Criteria
- B. Utilization of Skin Cancer Medications
- C. Prior Authorization of Skin Cancer Medications
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Skin Cancer Medications

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

10. Action Item – Annual Review of Antidepressants – See Appendix H

- A. Current Prior Authorization Criteria
- B. Utilization of Antidepressants
- C. Prior Authorization of Antidepressants
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Antidepressants

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

11. Annual Review of Complement Inhibitors and Miscellaneous Immunomodulatory Agents and 30-Day Notice to Prior Authorize Bkemy™ (Eculizumab-aeeb), Epysqli® (Eculizumab-aagh), Fabhalta® (Iptacopan), Piasky® (Crovalimab-akkz), and Voydeya™ (Danicopan) – See Appendix I

- A. Current Prior Authorization Criteria
- B. Utilization of Complement Inhibitors and Miscellaneous Immunomodulatory Agents

- C. Prior Authorization of Complement Inhibitors and Miscellaneous Immunomodulatory Agents
- D. Market News and Updates
- E. Product Summaries
- F. College of Pharmacy Recommendations
- G. Utilization Details of Complement Inhibitors and Miscellaneous Immunomodulatory Agents

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

12. Annual Review of Lysosomal Storage Disease Medications and 30-Day Notice to Prior Authorize Aqneursa™ (Levacetylleucine), Lenmeldy™ (Atidarsagene Autotemcel), and Miplyffa™ (Arimoclomol) – See Appendix J

- A. Current Prior Authorization Criteria
- B. Utilization of Lysosomal Storage Disease Medications
- C. Prior Authorization of Lysosomal Storage Disease Medications
- D. Market News and Updates
- E. Product Summaries
- F. College of Pharmacy Recommendations
- G. Utilization Details of Lysosomal Storage Disease Medications

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

13. Annual Review of Parathyroid Medications and 30-Day Notice to Prior Authorize Yorvipath® (Palopegteriparatide) – See Appendix K

- A. Current Prior Authorization Criteria
- B. Utilization of Parathyroid Medications
- C. Prior Authorization of Parathyroid Medications
- D. Market News and Updates
- E. Yorvipath® (Palopegteriparatide) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of Parathyroid Medications

Items to be presented by Dr. Metts, Dr. Muchmore, Chairman:

14. Annual Review of Osteoporosis Medications and 30-Day Notice to Prior Authorize Jubbonti® (Denosumab-bbdz) – See Appendix L

- A. Current Prior Authorization Criteria
- B. Utilization of Osteoporosis Medications
- C. Prior Authorization of Osteoporosis Medications
- D. Market News and Updates
- E. Jubbonti® (Denosumab-bbdz) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of Osteoporosis Medications

Items to be presented by Dr. Metts, Dr. Muchmore, Chairman:

15. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix M

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

16. Future Business* (Upcoming Product and Class Reviews)

No live DUR Board meeting scheduled for January 2025. January 2025 will be a packet-only meeting.

- A. Antihyperlipidemics
- B. Antihypertensive Medications
- C. Miscellaneous Cancer Medications
- D. Non-Steroidal Anti-Inflammatory Drugs

*Future product and class reviews subject to change.

Items to be presented by Dr. Muchmore, Chairman:

17. Action Item – Nomination of DUR Board Officers

- A. Nominations and Approval of DUR Board Chair and Vice Chair

18. Adjournment

NOTE: An analysis of the atypical [Aged, Blind, and Disabled (ABD)] patient subgroup of the Oklahoma Medicaid population has been performed pertaining to all recommendations included in this DUR Board meeting packet to ensure fair and knowledgeable deliberation of the potential impact of the recommendations on this patient population.

NOTE: Oklahoma Medicaid transitioned from a fee-for-service (FFS) pharmacy benefit to a managed care pharmacy benefit for most members on April 1, 2024. At that time, the majority of SoonerCare members were transitioned to one of the three managed care SoonerSelect plans: Aetna, Humana, or Oklahoma Complete Health. SoonerSelect data has been provided to the College of Pharmacy and has been used in analyses throughout this DUR Board meeting packet. The data included in this DUR Board meeting packet combines FFS and managed care utilization data. The managed care utilization reported in this packet is based solely on the data provided by the SoonerSelect plans.